BearishMEDIUM severityHealthcare & Pharma62d ago

Beta Bionics shares fall as company prices $150M stock offering at $17.25/share

Beta Bionics shares fall as company prices $150M stock offering at $17.25/share — $BBNX one-month chart
$BBNX daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about BBNX. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · beta bionicsEvent risk Low

Nothing reported about beta bionics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 110% a year
Now $15.21Week $12.85–$17.57 (±15.5%)Month $10.38–$20.04 (±31.8%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: This one turns on a concrete figure ($17.25); set it against the recent trend before reading it as a turning point.
  • How the stock is trading: $BBNX -7.37% in the latest session.
  • Timing: It was published before the opening bell, so the next session was the first chance to trade on it.
Amount$150 million
Amount$17.25

Where the stock stands

Beta Bionics ($BBNX) fell 7.37% to $15.21 in the latest session. Over the past month it is down 9.7%. That leaves it 54% below its 52-week high of $32.71 and 73% above its low of $8.80. It has been a volatile year: the high was 3.7 times the low, so moves this size are not unusual for it.

What the filings say

In its latest report (10-Q, filed Oct 27, 2026), $BBNX lost $24.4M over the quarter to Sep 30, 2026 on revenue of $35.5M (+10.9% QoQ). Operations used $50.7M of cash over the nine months to Sep 30, 2026 — about $5.7M a month — against $81.6M in cash on Sep 30, 2026. At that pace the cash covers about 14 months. Total liabilities were $42.4M against $81.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Sep 17, 1 day after this story; it is $BBNX's own account and the first thing to read. Figures are as filed with the SEC; the $BBNX page has the full statements.

How much coverage it is getting

This story is more than a month old. Since then Wook has filed one newer story on Beta Bionics in the last 30 days. It reads neutral.

The bigger picture

Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

For the company's side of it, read its latest SEC filings on the $BBNX page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $BBNX: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on September 16, 2026. $BBNX has moved -31.42% ($22.18 to $15.21). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy